{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:28:16Z","timestamp":1793500096730,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.02.039","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T07:27:25Z","timestamp":1645255645000},"page":"2003-2010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Impact of the Sinopharm\u2019s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)"],"prefix":"10.1016","volume":"40","author":[{"given":"Farida","family":"Ismail AlHosani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Eduardo Stanciole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashir","family":"Aden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Timoshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Najim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Abbas Zaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"AlSayedsaleh AlDhaheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereena","family":"Al Mazrouie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir Aziz","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.02.039_b0005","unstructured":"COVID-19 Dashboard at Johns Hopkins University. https:\/\/coronavirus.jhu.edu\/map.html. Accessed Feb. 13, 2022."},{"key":"10.1016\/j.vaccine.2022.02.039_b0010","unstructured":"COVID-19 vaccine tracker and landscape. World Health Organization. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines. Accessed Feb. 13, 2022."},{"key":"10.1016\/j.vaccine.2022.02.039_b0015","unstructured":"COVID-19 Vaccine Tracker. https:\/\/covid19.trackvaccines.org\/. Accessed Feb. 13, 2022."},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.039_b0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.02.039_b0025","unstructured":"World Health Organization (WHO) Guidelines. https:\/\/www.who.int\/news\/item\/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations. Accessed Oct. 18, 2021."},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.039_b0030","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.039_b0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2022.02.039_b0040","unstructured":"Khlaleej Times: https:\/\/www.khaleejtimes.com\/coronavirus-pandemic\/uaes-phase-iii-covid-19-inactivated-vaccine-trial-reaches-milestone-of-15000-volunteers. Accessed July 31, 2021."},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.039_b0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"issue":"7881","key":"10.1016\/j.vaccine.2022.02.039_b0050","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","article-title":"China\u2019s COVID vaccines have been crucial \u2014 now immunity is waning","volume":"598","author":"Mallapaty","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.02.039_b0055","unstructured":"Moustsen-Helms IR, Emborg HD, Nielsen J, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers \u2013 a Danish cohort study. medRxiv (Preprint) published online March 9 https:\/\/wwwdoiorg\/101101\/2021030821252200."},{"issue":"10277","key":"10.1016\/j.vaccine.2022.02.039_b0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(21)00448-7","article-title":"Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients","volume":"397","author":"Amit","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.039_b0065","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.15985","article-title":"Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization","volume":"4","author":"Chodick","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10285","key":"10.1016\/j.vaccine.2022.02.039_b0070","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet"},{"issue":"10286","key":"10.1016\/j.vaccine.2022.02.039_b0075","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.039_b0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.15585\/mmwr.mm7011e3","article-title":"Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021","volume":"70","author":"Britton","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"13","key":"10.1016\/j.vaccine.2022.02.039_b0085","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep"},{"key":"10.1016\/j.vaccine.2022.02.039_b0090","article-title":"An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status","volume":"ciab608","author":"Lumley","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.039_b0095","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-021-01410-w","article-title":"Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom","volume":"27","author":"Pritchard","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.02.039_b0100","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"issue":"10287","key":"10.1016\/j.vaccine.2022.02.039_b0105","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.vaccine.2022.02.039_b0110","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.039_b0115","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10787-021-00839-2","article-title":"Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies","volume":"29","author":"Kow","year":"2021","journal-title":"Inflammopharmacology"},{"issue":"24","key":"10.1016\/j.vaccine.2022.02.039_b0120","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.039_b0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.039_b0130","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.vaccine.2022.02.039_b0135","unstructured":"The UAE National Emergency Crisis and Disaster Management Authority (NCEMA) Coronavirus (COVID-19) updates: https:\/\/covid19.ncema.gov.ae\/en\/News\/List. Accessed Oct. 18, 2021."},{"key":"10.1016\/j.vaccine.2022.02.039_b0140","unstructured":"Our World in Data. United Arab Emirates: Coronavirus Pandemic Country Profile. https:\/\/ourworldindata.org\/coronavirus\/country\/united-arab-emirates?country=~ARE. Accessed Oct. 18, 2021."},{"key":"10.1016\/j.vaccine.2022.02.039_b0145","unstructured":"World Health Organization (WHO) Interim Guidance on the \u201cEvaluation of COVID-19 vaccine effectiveness\u201d. March 17, 2021. https:\/\/apps.who.int\/iris\/handle\/10665\/340301. Accessed July 31, 2021."},{"key":"10.1016\/j.vaccine.2022.02.039_b0150","unstructured":"Hindustan Times: https:\/\/www.hindustantimes.com\/world-news\/explained-why-uae-is-witnessing-a-surge-in-number-of-covid-19-cases-101612066414167.html. Accessed July 31, 2021."},{"key":"10.1016\/j.vaccine.2022.02.039_b0155","unstructured":"Bloomberg: https:\/\/www.bloomberg.com\/news\/articles\/2021-02-28\/uae-cases-drop-22-from-late-january-peak-lagging-uk-and-israel. Accessed July 31, 2021."},{"issue":"9","key":"10.1016\/j.vaccine.2022.02.039_b0160","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.2021.1114","article-title":"SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants","volume":"325","author":"Moore","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.02.039_b0165","unstructured":"Centers for Disease Control (CDC). https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant.html. Accessed July 31, 2021."},{"key":"10.1016\/j.vaccine.2022.02.039_b0170","unstructured":"The UAE National Emergency Crisis & Disaster Management Authority (NCEMA): https:\/\/twitter.com\/NCEMAUAE\/status\/1409226693366226948?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1409226693366226948%7Ctwgr%5E%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fgulfbusiness.com%2Fcovid-19-delta-variant-accounts-for-a-third-of-all-infections-in-the-uae%2F. Accessed July 31, 2021."},{"key":"10.1016\/j.vaccine.2022.02.039_b0175","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41467-022-28089-y","article-title":"Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.02.039_b0180","unstructured":"Associated Press (AP) News: https:\/\/apnews.com\/article\/middle-east-coronavirus-pandemic-health-8d517a96e6fcf585bda77d16ebad139a. Accessed July 31, 2021."},{"key":"10.1016\/j.vaccine.2022.02.039_b0185","unstructured":"Saudia Airline Travel Updates: https:\/\/www.saudia.com\/before-flying\/travel-information\/travel-requirements-by-international-stations. Accessed July 31, 2021."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22001748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22001748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:14Z","timestamp":1759403414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22001748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X22001748"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the Sinopharm\u2019s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}